Related Experiment Video
Updated: May 23, 2026

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
Emerging pharmacotherapies for diabetic macular edema
Golnaz Javey1, Stephen G Schwartz, Harry W Flynn
1Department of Ophthalmology, Baylor College of Medicine, 7200-B Cambridge Street, Houston, TX 77030, USA.
Abstract:
Diabetic macular edema (DME) remains an important cause of visual loss in patients with diabetes mellitus. Although photocoagulation and intensive control of systemic metabolic factors have been reported to achieve improved outcomes in large randomized clinical trials (RCTs), some patients with DME continue to lose vision despite treatment. Pharmacotherapies for DME include locally and systemically administered agents. We review several agents that have been studied for the treatment of DME.
Related Concept Videos
Diabetic Retinopathy
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Angle Closure Glaucoma: Treatment
Diabetic Nephropathy
Ophthalmic Drug Delivery Systems